09:45 AM EST - Endo International plc : And Acerus Pharmaceuticals Corporation announced the completion of the NATESTO® U.S. transition from an affiliate of Endo, back to Acerus, and subsequently to Aytu BioScience, Inc. Aytu will now assume responsibility for the U.S. commercialization of NATESTO®, the first and only FDA-approved testosterone nasal gel indicated for replacement therapy in adult males diagnosed with hypogonadism. Endo International plc
shares T.ENL are trading unchanged at $21.82.
